Episodic Cluster Headache: What to Do When Acute Treatments Don’t Achieve 30-Minute Headache Relief
Clinical Scenario
This protocol targets episodic cluster headache (ICHD-3 3.1.1) — the most common pattern — characterised by symptomatic periods lasting from 7 days to several months, separated by symptom-free intervals of at least 3 months.
Prior Acute Treatment — Goal Not Met
The previous treatment line — which included nasal spray triptans (zolmitriptan, sumatriptan), noninvasive vagus nerve stimulation, dihydroergotamine nasal spray, and/or intranasal lidocaine — did not achieve headache relief within 30 minutes of administration. Failure to reach this target is the trigger for escalation to a structured preventive approach.
Treatment Goal
At least 50% reduction in attack frequency, with preventive efficacy expected after 2–3 weeks of treatment.
References
DOI: 10.1111/ene.15956
- the majority of patients experience an episodic pattern (80%, ICHD-3 3.1.1), with symptomatic periods (7 days to several months, most commonly 4–12 weeks) and symptom-free periods of variable duration (minimum of 3 months).
- Initial preventive treatment of cluster headache is usually verapamil at a daily dose of at least 240 mg.
- In clinical practice, most clinicians start up with 80 mg 3–4 times per day.
- Corticosteroids can be used for short periods where bouts are short or to help establish another medication.
- Pharmacological nerve block of the GON is recommended and can be repeated if efficacious.
- Based on consensus, ergotamine tartrate or frovatriptan are also recommended for short-term prevention.
- The responder rate defined as 50% reduction in headache frequency was 80%.